echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The risk of progression of thyroid cancer disease was reduced by 78% in phase 3 clinical trials of poly kinase inhibitors

    The risk of progression of thyroid cancer disease was reduced by 78% in phase 3 clinical trials of poly kinase inhibitors

    • Last Update: 2021-02-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Differentiated thyroid tumors account for about 90% of thyroid cancer cases, and the typical treatment is surgical treatment and then the ablation of the remaining thyroid tissue with radioactive iodine, but about 5% to 15% of cases are resistant to radioactive iodine therapy.
    for these patients, life expectancy is only three to six years, starting with the discovery of metastasis lesions.
    Cabometyx is a multi-kinase inhibitor that inhibits c-Met, VEGFR2, Axl and Ret.
    has been approved by the FDA to treat patients with advanced renal cell carcinoma and 1st-century patients with hepatocellular carcinoma who have previously been treated with sorafenib.
    In a critical Phase 3 clinical trial called COSMIC-311, randomized double-blind, placebo-containing control, about 300 patients with radioactive iodine incurable differentiated thyroid cancer were treated with Cabometyx or a placebo.
    patients had previously been treated with up to two VEGFR targeted therapies, but the disease continued to progress.
    results of the trial will be presented at a future medical conference.
    : s1. Exelixis Announces Cabozantinib GreatEry Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Rogered Thyroid Cancer. Retrieved December 21, 2020, from
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.